Cordycepin is also a Phase I/II clinical stage drug candidate for treatment of refractory acute lymphoblastic leukemia (ALL) patients who express the enzyme terminal deoxynucleotidyl transferase (TdT) (http://www.ClinicalTrials.Gov verified by OncoVista, Inc., 2009). Here, DNTT is linked to acute lymphoblastic leukemia.